CHRS Forecast — Price Target — Prediction for 2027
The article provides a forecast and price target for Coherus Oncology, Inc. (CHRS) stock, outlining analysts' predictions and historical performance data. It details the company's current stock price, market capitalization, volatility, and future earnings estimates, alongside historical highs and lows. The information is presented as a financial overview for potential investors, noting that it is not investment advice.
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
Coherus Oncology and Zumutor Biologics have announced a clinical collaboration and supply agreement for a Phase 1 trial evaluating ZM008, an anti-LLT1 monoclonal antibody, in combination with Coherus's PD-1 inhibitor, LOQTORZI. The study will enroll patients with various solid tumors, with the goal of expanding LOQTORZI indications and strengthening clinical data. This partnership aims to leverage complementary immune pathways to treat hard-to-treat cancers and identify predictive biomarkers for personalized therapies.
Coherus BioSciences Inc (CHRS) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Coherus BioSciences Inc (CHRS), noting its current valuation score of 9.20, which ranks 44th in the Pharmaceuticals industry. It highlights that the company's current P/E ratio is 0.85, significantly lower than its recent high but higher than its recent low. The article also states that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Coherus BioSciences Inc (CHRS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Coherus BioSciences Inc (CHRS), identifying major individual and institutional holders, along with their respective proportions. It also presents a breakdown of shareholder types, including investment advisors, corporations, and hedge funds. Furthermore, the piece provides a
Coherus BioSciences Inc (CHRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Coherus BioSciences Inc (CHRS), categorizing its revenue by business segment and by region. For the reported period, UDENYCA accounted for the vast majority of revenue at 99.24%, followed by CIMERLI and YUSIMRY. Geographically, all reported revenue came from the United States.
Coherus BioSciences Inc (CHRS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Coherus BioSciences Inc (CHRS) has an earnings forecast score of 8.57, ranking 27th in the Pharmaceuticals industry. Analysts have set an average price target of $5.00 for CHRS, with a "Buy" rating based on the consensus of seven analysts. The company's expected revenue for the next quarter is $14.60M, and EPS is forecasted at -$0.14.
Coherus Oncology appoints PwC as new auditor, replaces Ernst & Young By Investing.com
Coherus Oncology has appointed PricewaterhouseCoopers LLP (PwC) as its new independent auditor, replacing Ernst & Young LLP, effective June 12, 2026. The change follows the dismissal of Ernst & Young by the Audit Committee, with Coherus Oncology stating no disagreements on accounting principles that would have required mention in past audit reports, despite a previously remediated material weakness in internal control. This announcement comes amid other recent company news, including a Q1 2026 EPS alignment but revenue shortfall, and the election of new Class III directors at its annual meeting.
Coherus Oncology appoints PwC as new auditor, replaces Ernst & Young
Coherus Oncology has announced the dismissal of Ernst & Young LLP as its independent auditor, effective June 12, and the appointment of PricewaterhouseCoopers LLP (PwC) for the fiscal year ending December 31, 2026. The company stated that there were no disagreements on accounting principles or audit procedures with Ernst & Young, although a material weakness in internal controls from 2024 was remediated by 2025 year-end. This change follows recent financial news, including the company's Q1 2026 earnings and the election of new Class III directors.
[8-K] Coherus Oncology, Inc. Reports Material Event
Coherus Oncology, Inc. filed an 8-K report announcing a change in its independent auditing firm. On June 12, 2026, the company dismissed Ernst & Young LLP and appointed PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2026, subject to standard acceptance procedures. EY confirmed no adverse opinions or disagreements in their past audits, although a material weakness in internal controls for inventory reconciliations was previously reported and has since been remediated.
Coherus Oncology (CHRS) director receives 30K RSUs and 60K stock option grant
Coherus Oncology director Ali J. Satvat was granted 30,000 restricted stock units (RSUs) and a stock option for 60,000 shares on June 5, 2026. The RSUs vest 100% on June 3, 2027, and the stock option, with an exercise price of $1.45, becomes fully exercisable on June 3, 2027. Both awards are contingent on his continued service with the company.
[Form 4] Coherus Oncology, Inc. Insider Trading Activity
This article reports on insider trading activity at Coherus Oncology, Inc. (CHRS) from a Form 4 filing. It details two transactions by insider Ryan Michael Lee, involving the grant of 30,000 shares of common stock and 60,000 stock options, both vesting over time. The filing impact and sentiment are classified as neutral.
Coherus Oncology shareholders approve director elections and equity plan changes
Coherus Oncology shareholders held their 2026 Annual Meeting, electing two Class III directors, Dennis M. Lanfear and Mats L. Wahlström, and ratifying Ernst & Young LLP as their independent public accounting firm. They also approved a non-binding advisory resolution on executive compensation, reduced the exercise price of certain stock options, and increased shares reserved for their equity incentive plan. These decisions follow the company's recent Q1 2026 earnings report, which met EPS expectations but showed a revenue shortfall.
Coherus Oncology (CHRS) shareholders approve equity plan changes and option repricing
Coherus Oncology, Inc. shareholders approved all proposals at their 2026 annual meeting, including the election of Class III directors, ratification of Ernst & Young LLP as auditor, and a non-binding Say-on-Pay resolution. Key equity-related approvals included a reduction in the exercise price of certain outstanding stock options and an increase in shares reserved under the Amended and Restated 2014 Equity Incentive Award Plan. These approvals are expected to affect future dilution and employee incentives for the company.
Coherus (NASDAQ: CHRS) reprices 3.2M CEO stock options to $1.59
Coherus Oncology, Inc. announced the repricing of 3.2 million stock options for President & CEO Dennis M. Lanfear to an exercise price of $1.59 per share. These new options replace older ones with significantly higher exercise prices, a move approved by stockholders on May 29, 2026, and contingent on Lanfear remaining with the company through May 29, 2027. This adjustment aims to re-align his compensation with the current share price and provide new incentives.
Coherus Biosciences Announces 2026 Stockholder Meeting Results
Coherus Biosciences (CHRS) announced the results of its 2026 Annual Meeting of Stockholders. Key outcomes include the election of Class III directors, ratification of Ernst & Young LLP as auditor, approval of executive compensation, and a reduction in the exercise price of certain stock options. Stockholders also authorized an increase in shares for its equity incentive plan to attract and retain talent.
Coherus Oncology shareholders approve director elections and equity plan changes
Coherus Oncology shareholders approved the election of two Class III directors, ratified the appointment of Ernst & Young LLP as their accounting firm, and approved executive compensation. Additionally, shareholders voted to reduce the exercise price of certain stock options and increase shares reserved under the 2014 Equity Incentive Award Plan. These decisions were made during their 2026 Annual Meeting of Stockholders, which included a partial adjournment for one proposal.
CHRS - Coherus Oncology Inc Stock Price and Quote
This article provides comprehensive stock information for Coherus Oncology Inc. (CHRS), including its latest stock price, financial overview, analyst ratings, and recent news. Key data points cover market capitalization, P/E ratios, EPS, sales figures, and insider/institutional ownership, alongside performance metrics across various timeframes. The news section highlights corporate activities like earnings calls, clinical collaborations, financial results, and strategic transformations, emphasizing the company's shift towards innovative cancer therapeutics.
Coherus Oncology (CHRS) CFO receives repriced $1.59 stock options, cancels higher-strike grants
Coherus Oncology's CFO, Bryan J. McMichael, received new stock options on May 29, 2026, with an exercise price of $1.59 per share, totaling 220,000 shares. Simultaneously, previously granted options with higher exercise prices, ranging from $5.44 to $14.76 per share, were disposed of back to the issuer as part of a stockholder-approved repricing initiative. This repricing affects options previously priced at or above $5, aiming to reset them at the new $1.59 exercise price, contingent on the CFO's continued service through May 29, 2027.
Coherus BioSciences stock (US19247A1007): short interest remains elevated as investors watch oncology pipeline
Coherus BioSciences (CHRS) continues to experience high short interest and volatile trading as investors assess its oncology and biosimilar portfolios. The company, a US biotechnology firm, is strategically shifting towards high-margin oncology assets while managing its legacy biosimilar products. Investors are closely monitoring clinical trial data, regulatory milestones, and market dynamics to gauge the company's future financial performance and competitive position.
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
Coherus Oncology reported its first-quarter 2026 financial results, highlighting LOQTORZI® net revenue of $11.8 million, a 61% increase year-over-year. The company also provided updates on its pipeline, including the completion of patient accrual for the 1L HCC Phase 2 clinical trial for casdozokitug and progress in the tagmokitug development program. Coherus ended the quarter with $167.0 million in cash, cash equivalents, and marketable securities.
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
Coherus Oncology announced its first-quarter 2026 financial results, reporting $11.8 million in LOQTORZI net revenue, a 61% increase year-over-year. The company provided updates on its oncology pipeline, including the completion of patient accrual for the casdozokitug Phase 2 trial and advancements in the tagmokitug program. Coherus ended the quarter with $167.0 million in cash, cash equivalents, and marketable securities.
Earnings call transcript: Coherus BioSciences Q1 2026 revenue misses forecast
Coherus BioSciences reported Q1 2026 revenue of $12.31 million, falling short of the $14.43 million forecast, but its EPS of -$0.25 met expectations. Despite the revenue miss, the company's shares rose 11.43% in after-hours trading, driven by investor optimism about future growth and strategic initiatives. Key products like LOQTORZI showed significant year-over-year growth, and management expects a rebound from weather-related impacts in Q2 2026.
Coherus BioSciences Inc CHRS
This page provides an overview of Coherus BioSciences Inc. (CHRS) stock, including its current price, market cap, and P/E ratio. It shows the stock closed at $1.950 with an 11.43% increase on May 11th. The platform also offers various financial analysis tools and news for investors.
Coherus (CHRS) Reports Q1 Revenue Below Expectations
Coherus BioSciences (CHRS) announced Q1 revenue of $12.31 million, falling short of the anticipated $14.34 million. The company, which has a GF Score™ of 51/100, is focusing on its LOQTORZI product for neuroendocrine prostate cancer and other pipeline products, despite facing challenges in financial strength and profitability. Investors are advised to be cautious due to the revenue shortfall, low GF Score™, and minimal insider activity.
Coherus Oncology (CHRS) grows Q1 2026 revenue as losses narrow and cash hits $167M
Coherus Oncology reported a notable increase in Q1 2026 revenue to $12.3 million from $7.6 million year-over-year, primarily driven by LOQTORZI sales totaling $11.8 million. The company successfully narrowed its GAAP net loss from continuing operations to $36.9 million and maintained a cash position of $167.0 million, signaling progress in its oncology transition while continuing development for key pipeline candidates like tagmokitug and casdozokitug.
Coherus Biosciences Inc (CHRS) Stock News & Articles
This page provides an overview of Coherus BioSciences Inc (CHRS), a biopharmaceutical company specializing in biosimilars and immuno-oncology treatments. It details the company's key products like UDENYCA, CIMERLI, and YUSIMRY, and highlights its strategic partnerships aimed at affordable healthcare solutions. The page also features a recent article discussing Wall Street analyst research calls, including one relevant to Coherus Oncology.
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
Coherus Oncology, Inc. announced it will release its first quarter 2026 financial results after market close on Monday, May 11, 2026. The company's management will host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a business update. A replay of the webcast will be available on the investors section of their website.
Satterfield reports 6.93M shares in Coherus Oncology (NASDAQ: CHRS) ownership filing
Thomas A. Satterfield, Jr. has filed a Schedule 13G/A, reporting beneficial ownership of 6.93 million shares, or 4.6%, of Coherus Oncology (NASDAQ: CHRS) common stock. This includes shares held jointly, through various entities he controls, and via limited powers of attorney for other holders. The filing details both sole and shared voting/dispositive power over these shares.
Coherus Oncology announces proposed public offering of common stock
Coherus BioSciences announced a proposed public offering of its common stock. The offering is subject to market and other conditions. All shares are to be offered by Coherus, and a lead book-running manager, Cantor, along with Oppenheimer & Co., are acting as book-running managers.
[DEF 14A] Coherus Oncology, Inc. Definitive Proxy Statement
Coherus Oncology, Inc. has filed a definitive proxy statement (DEF 14A) for its virtual 2026 annual meeting on May 27, 2026. Stockholders will vote on director elections, auditor ratification, executive compensation, a one-time stock option repricing, and an increase in the equity incentive pool. The Board recommends voting "FOR" all proposals, emphasizing the importance of equity incentives for retention and aligning employee interests with stockholders.
Coherus Oncology (CHRS) proposes option repricing and 7.7M-share increase
Coherus Oncology (CHRS) has filed a preliminary proxy statement for its 2026 Annual Meeting, proposing a one-time repricing of 9.54 million employee and consultant stock options and a 7.7 million share increase to its 2014 Equity Incentive Award Plan. The option repricing aims to restore incentive by resetting exercise prices to the closing price on the meeting date, with an extension of terms, while the share increase is crucial for talent attraction and retention in its transition to an oncology company. The Board recommends a "FOR" vote on all proposals, asserting they are in the best interest of the company and stockholders.
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Hold" by Brokerages
Coherus Oncology, Inc. (NASDAQ:CHRS) has received an average "Hold" recommendation from five research firms, with analysts providing one sell, one hold, and three buy ratings. The average 1-year target price for the stock is $5.5125. Major institutional investors and hedge funds hold 72.82% of the company's stock, and Coherus Oncology recently reported Q4 earnings per share of ($0.34), missing analyst expectations.
Coherus Biosciences (CHRS) Is One of the Best Penny Stocks, Here is Why
Coherus Oncology Inc. (NASDAQ: CHRS) is identified as a top penny stock with potential to triple money, following its Q4 2025 earnings report. The company showed progress with increased LOQTORZI sales and significant debt reduction, signaling a transition towards an oncology-focused business. Management anticipates further growth through revenue, partnerships, and clinical catalysts in 2026 for its immunotherapy pipeline.
If You Invested $1,000 in Coherus (CHRS)
This article analyzes the historical performance of a $1,000 investment in Coherus (CHRS) over 1, 5, and 10 years, detailing significant losses over the longer terms and underperformance against the S&P 500. It also provides an overview of Coherus Oncology, Inc.'s focus on developing and commercializing antibody-based cancer therapies, highlighting its key product LOQTORZI and pipeline candidates like CHS-114 and casdozokitug. The company's strategic emphasis on combination therapies for various solid tumors and its corporate information are also discussed.
Metastatic Hepatocellular Carcinoma Clinical Trial Pipeline
DelveInsight's report highlights significant advancements in the Metastatic Hepatocellular Carcinoma (HCC) pipeline, with over 20 companies and 25+ pipeline drugs in development. Key clinical trial updates include Coherus Oncology Inc.'s Phase 2 trial for SRF388 and AstraZeneca's Phase I/II study for AZD5851. The report details several promising emerging drugs like CS1003, Casdozokitug, TTI-101, and ST316, emphasizing the robust research efforts to address this challenging cancer.
Coherus Oncology announces proposed public offering of common stock
Coherus BioSciences, Inc. (CHRS) announced a proposed public offering of its common stock. The offering will be underwritten by Jefferies and TD Cowen as joint book-running managers. The company intends to grant the underwriters a 30-day option to purchase additional shares.
Coherus BioSciences Q4 2025 earnings preview
This article provides an earnings preview for Coherus BioSciences' Q4 2025 results. Investors will be looking for key metrics such as EPS, revenue, and any guidance provided for the upcoming year. The article's main purpose is to inform readers about the impending financial report.
Coherus Oncology, Inc. (NASDAQ:CHRS) Receives Consensus Recommendation of "Hold" from Analysts
Coherus Oncology, Inc. (NASDAQ:CHRS) has received a consensus "Hold" recommendation from five research firms, with an average one-year price target of $5.51. Oppenheimer recently initiated coverage with an "Outperform" rating and a $10.00 target. The company's shares are trading at $1.69 after missing quarterly EPS and revenue estimates, and analysts forecast a full-year EPS of approximately -1.05.
Coherus BioSciences Q4 2025 earnings preview
This article provides a Q4 2025 earnings preview for Coherus BioSciences. It likely discusses expectations for the company's financial performance in the upcoming earnings report.
Oppenheimer reiterates Coherus Biosciences stock rating at Outperform
Oppenheimer has reiterated an Outperform rating and a $10.00 price target for Coherus Biosciences (NASDAQ:CHRS), highlighting the stock's recent rebound and undervalued status despite fourth-quarter 2025 sales missing consensus. The firm remains optimistic about the company's pipeline opportunities, particularly with key readouts scheduled for 2026 and plans to expand Loqtorzi's market footprint. Recent financial maneuvers, including a public offering and a clinical supply agreement, further support Oppenheimer's positive outlook.
Oppenheimer reiterates Coherus Biosciences stock rating at Outperform
Oppenheimer has reiterated an Outperform rating and $10.00 price target for Coherus Biosciences (NASDAQ:CHRS), highlighting the company's strong pipeline opportunity and the stock's undervaluation. Despite some earlier weakness, Coherus Biosciences has seen a significant rebound, with shares surging 36% year-to-date, driven by anticipated key readouts in 2026 for its Loqtorzi and tagmokitug programs. The firm believes the market is underappreciating Coherus's potential, especially with planned investments in commercial infrastructure and recent financial and strategic maneuvers like a public offering and a clinical supply agreement with Johnson & Johnson.
COHERUS BIOSCIENCES ($CHRS) Releases Q4 2025 Earnings
COHERUS BIOSCIENCES ($CHRS) reported its Q4 2025 earnings, with an EPS of -$0.34, beating estimates by $0.02, but revenue of $12,750,000 missed estimates by over $1.4 million. Following the report, the company's stock price decreased by 6.15% since market close. The article also details recent hedge fund activity, showing significant decreases in holdings by some institutional investors while others substantially increased their positions.
Coherus Oncology Q4 2025 Results: Quarterly Loss, Annual Profit - News and Statistics
Coherus Oncology reported a loss of $37.6 million in its fourth quarter of 2025, or 31 cents per share, which adjusted to 34 cents per share. The drug developer's revenue for the quarter was $12.7 million, missing Street forecasts. However, for the entire year, the company posted a profit of $168 million, or $1.43 per share, with total revenue reaching $42.2 million.
Cancer drug LOQTORZI sales double to $40.8M as trials near
Coherus Oncology (NASDAQ: CHRS) reported significant financial results for the full year and fourth quarter of 2025, with LOQTORZI revenue more than doubling to $40.8 million. The company also drastically reduced its secured and convertible debt by approximately 90% to $38.8 million and ended the year with $172.1 million in cash and marketable securities. Coherus is aggressively advancing its oncology pipeline with multiple clinical readouts expected in 2026 for tagmokitug and casdozokitug.
Coherus BioSciences (CHRS) Q4 Earnings Preview: What to Expect
Coherus BioSciences (CHRS) is expected to report a significant decline in EPS and revenue for Q4, with analysts forecasting -$0.31 EPS and $14.09 million in revenue. The biotechnology company, focusing on oncology, shows financial distress indicators like a negative Altman Z-Score and declining revenue growth. Despite the financial challenges, its strategic focus on expanding the oncology pipeline offers potential long-term growth, though near-term risks remain significant.
Coherus BioSciences's Earnings Outlook
Coherus BioSciences (NASDAQ: CHRS) is expected to release its quarterly earnings report on March 9, 2026, with an estimated EPS of $-0.34. The company's financial health shows notable revenue growth of 91.19% and a strong net margin of -307.07%, despite a high debt-to-equity ratio and lower-than-average market capitalization. Shares have increased by 68.75% over the last 52 weeks, heading into the earnings release.
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
Coherus Oncology, Inc. (Nasdaq: CHRS) announced it will release its full-year and fourth-quarter 2025 financial results on Monday, March 9, 2026, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a business update. A webcast replay and related materials will be available on the investor relations section of their website.
Coherus Oncology, Inc. to Release 2025 Financial Results on March 9, 2026, with Conference Call to Follow
Coherus Oncology, Inc. announced it will release its full year and fourth quarter 2025 financial results on March 9, 2026, after market close, followed by a conference call and webcast at 4:30 p.m. Eastern Time. The company, focused on oncology with its approved PD-1 inhibitor LOQTORZI®, will discuss the results and provide a business update, with a webcast replay available on its website. This release highlights the company's commitment to transparency and stakeholder engagement while providing an overview of its pipeline candidates.
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
Coherus Oncology, Inc. announced it will release its full year and fourth quarter 2025 financial results after market close on Monday, March 9, 2026. Management will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a business update. The company is a commercial-stage oncology firm with an approved PD-1 inhibitor, LOQTORZI, and a pipeline of clinical candidates targeting various cancers.
Coherus investor talks stream online from Boston and Miami
Coherus Oncology (NASDAQ: CHRS) announced that its senior management will present at two investor conferences in March 2026: the TD Cowen Healthcare Conference in Boston on March 4, 2026, and the Citizens Life Sciences Conference in Miami on March 10, 2026. Webcasts and replays of these presentations will be available for approximately 90 days on the company's investor events calendar. The news of these presentations led to a mild negative market reaction, with CHRS declining 0.61% on the day this information was published.
